GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy
出版年份 2023 全文链接
标题
GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy
作者
关键词
-
出版物
iScience
Volume 26, Issue 11, Pages 108165
出版商
Elsevier BV
发表日期
2023-11-03
DOI
10.1016/j.isci.2023.108165
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy
- (2022) Thomas S. Uldrick et al. Science Translational Medicine
- Immune checkpoint blockade in HIV
- (2022) Celine Gubser et al. EBioMedicine
- HIV-specific T-cell responses reflect substantive in vivo interactions with antigen despite long-term therapy
- (2021) Eva M. Stevenson et al. JCI Insight
- Gag p24 is a Marker of HIV Expression in Tissues and Correlates with Immune Response
- (2021) Guoxin Wu et al. JOURNAL OF INFECTIOUS DISEASES
- Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy
- (2021) Chris Y. Chiu et al. JOURNAL OF IMMUNOLOGY
- Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
- (2021) Steven G. Deeks et al. NATURE MEDICINE
- Combination Immune Checkpoint Blockade to Reverse HIV Latency
- (2020) Renée M. Van der Sluis et al. JOURNAL OF IMMUNOLOGY
- Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
- (2020) Leitao Sun et al. Scientific Reports
- First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
- (2020) Ravit Geva et al. CANCER
- Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
- (2020) Ani S. Balmanoukian et al. CLINICAL CANCER RESEARCH
- Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors
- (2020) Kyriakos P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals
- (2019) Rémi Fromentin et al. Nature Communications
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy
- (2019) Bernard J.C. Macatangay et al. AIDS
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
- (2018) Ben Tran et al. Journal for ImmunoTherapy of Cancer
- Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection
- (2017) Matías T. Angerami et al. Frontiers in Immunology
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection
- (2016) Glen M. Chew et al. PLoS Pathogens
- CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
- (2016) Rémi Fromentin et al. PLoS Pathogens
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
- (2016) Mira A. Patel et al. Journal for ImmunoTherapy of Cancer
- Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+Regulatory T Cells Are Depleted
- (2015) Young H. Kim et al. JOURNAL OF IMMUNOLOGY
- Enhanced CD8 T Cell Responses through GITR-Mediated Costimulation Resolve Chronic Viral Infection
- (2015) Maria Fernanda Pascutti et al. PLoS Pathogens
- Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease
- (2014) Leslie R. Cockerham et al. AIDS
- Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC
- (2014) Derek L. Clouthier et al. JOURNAL OF IMMUNOLOGY
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Modulation of Treg cells/T effector function by GITR signaling is context-dependent
- (2013) Amal Ephrem et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Modulation of GITR for cancer immunotherapy
- (2012) David A Schaer et al. CURRENT OPINION IN IMMUNOLOGY
- Maintaining the balance: Costimulatory TNFRs and control of HIV
- (2012) Chao Wang et al. CYTOKINE & GROWTH FACTOR REVIEWS
- The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses
- (2011) Brenda De Keersmaecker et al. JOURNAL OF LEUKOCYTE BIOLOGY
- CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection
- (2010) L. M. Snell et al. JOURNAL OF IMMUNOLOGY
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
- (2010) Adam D. Cohen et al. PLoS One
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
- (2009) Nicolas Chomont et al. NATURE MEDICINE
- The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells
- (2008) Johanna Kober et al. EUROPEAN JOURNAL OF IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started